Fecal transplant programs are hunting for donors with exceptional microbial fitness
The modern stool bank is built on an uncomfortable but clinically serious premise: a carefully screened human donor can transfer a microbial community that restores gut health more effectively than many drugs. In fecal microbiota transplantation for recurrent Clostridioides difficile infection, the donor’s stool is not treated as waste. It is treated as a biologic product, and the screening standards reflect that level of risk.
The attention now being paid to donor quality has widened as fecal transplants move beyond recurrent C. difficile and into conditions such as ulcerative colitis, irritable bowel syndrome, diabetes, autism, osteoporosis, cognitive decline, and mental illness. Those newer uses remain far less settled than the approved role in C. difficile, but they have pushed clinicians to ask a sharper question: if the therapy works by moving microbes, which microbes, from which donor, and under what conditions make the difference?
Screening is closer to organ donation than routine lab work
A stool donor first goes through health questionnaires, interviews, blood work, and stool testing. The screening panel can include more than 30 pathogens, parasites, and multidrug-resistant organisms, and some programs also test for Covid-19 and influenza. Donors are also reviewed for autoimmune disease, mental health history, recent medications, supplements, travel, and even recent food exposures. In some laboratories, multivitamins and iron are scrutinized. In others, a donor may need to provide what clinicians jokingly call “nut-free poo.”
The process is deliberately severe because stool is a vehicle for transmission as well as treatment. Infectious organisms can move through fecal material, and fecal microbiota transplantation has previously been linked to transmission of E. coli in safety alerts. Even common respiratory infections can intersect with fecal contamination through toilet aerosolization, which is why clinics do not treat donor screening as a formality.
Age is part of the filter, too. Donors commonly fall between 18 and 48 years old, while recipients may be far older. The clinical reach is broad; treated patients have ranged from teenagers to nonagenarians. The donor pool, by contrast, is tiny. One clinician described roughly 3% of candidates passing initial screening, with about half of those considered suitable for repeated donation. Another program reported only 1.6% passing initial screening and about 0.6% remaining as regular donors.
Rarely does a medical intervention depend so heavily on everyday habits. Diet, exercise, sleep, alcohol intake, and even body habitus are folded into donor selection because they can shape the gut microbiome long before any sample reaches a recipient.
The best stool is not defined by one laboratory result
One of the striking problems in fecal transplantation is that a donor who is acceptable for one disease is not necessarily effective for another. For recurrent C. difficile, stool from any qualifying donor may work about as well as another, but the same is not true across all indications. In ulcerative colitis, donor-specific effects have emerged in clinical studies. In one 2015 study of fecal transplant for ulcerative colitis, 9 of 38 patients entered remission, and 7 of those remissions traced back to the same donor. In a 2017 study that used pooled stool from up to seven donors, recipients whose mixture included material from one particular donor were about twice as likely to improve as those whose mixture lacked it.
The biology makes sense even if the clinical prediction remains crude. Some donors appear to carry a broader and more robust microbial ecosystem, with species that may help re-establish intestinal balance. Faecalibacterium prausnitzii stands out because it is associated with butyrate production, a short-chain fatty acid that helps reduce inflammation and supports the intestinal lining. A donor rich in such organisms may therefore be better suited to diseases driven by mucosal inflammation than to disorders shaped by a different microbial problem.
One sentence captures the field’s frustration: no one yet knows how to reliably identify a super pooper before the sample is in hand.
The donor profile is valuable, but the recipient may matter just as much
The idea of a “super pooper” suggests that donor quality alone determines success. The data are less tidy. Investigators increasingly suspect that compatibility between donor and recipient may matter more than a single universal ideal. A stool donor with the right microbial profile may still fail in a recipient whose gut environment cannot support engraftment. That may explain why microbial transfer can appear dramatic in one condition and disappoint in another, even when the same donor pool is used.
This is also why the field is moving toward categorizing both donors and patients by microbial traits rather than chasing an abstract perfect stool. The gut is not an empty container. It is a complex ecosystem with its own immune pressures, nutritional inputs, prior antibiotic exposure, and inflammatory history. A transplant that succeeds in a colon dominated by recurrent C. difficile may not behave the same way in ulcerative colitis, IBS, or neuropsychiatric disease.
From raw stool to standardized microbiome products
Even the most successful donor program is labor-intensive. Some donors are asked to attend the lab nearly every day to produce a sample in a designated toilet. Banks often pay for each donation, and repeated use of the same donor is more efficient than recruiting new volunteers every time. That arrangement creates an unusual clinical relationship, one that balances trust, privacy, and the practical need for consistent product quality.
Preparation itself is also highly manual. Stool may be blended into a slurry, filtered through multiple fine meshes, mixed with saline, and frozen for later use. Fresh delivery appears to perform better in some studies, but freezing makes distribution more feasible. Administration can occur by colonoscopy, enema, or oral capsule. The approved products on the market reflect a push away from improvised transplantation and toward more standardized microbial therapies.
REBYOTA, a donor-derived enema product from Ferring Pharmaceuticals, and VOWST, an oral capsule made from bacterial spores and produced by Seres Therapeutics, are both approved for recurrent C. difficile infection. They point to a future in which the therapeutic unit may no longer be a messy whole stool sample but a curated microbial formulation grown or refined at scale.
Microbiome medicine is becoming more precise, but its limits remain visible
The appeal of fecal transplantation is obvious: a biological community, rather than a single molecule, can be moved into place to correct dysbiosis. The hazard is equally obvious: transplanting a whole microbial ecosystem introduces variability that pharmaceutical manufacturing usually tries to eliminate. Different donors, different preparations, and different recipients can all produce different outcomes, which makes reproducibility difficult.
For now, C. difficile remains the clearest success story. Beyond that, the field is still sorting signal from enthusiasm. Screening may protect patients from obvious infectious risk, but it does not yet reveal which stool will work best for a specific disease. Until microbiome testing becomes more predictive, donor selection will remain part science, part experience, and part educated trial.
The next meaningful advance is unlikely to come from finding one mythical donor whose stool works for everything. It will probably come from learning how to match microbial properties to disease biology, then reproducing those properties in a safer, more standardized product.
- • PubMed PMID 25857665: https://pubmed.ncbi.nlm.nih.gov/25857665/
- • PubMed PMID 28214091: https://pubmed.ncbi.nlm.nih.gov/28214091/